



February 22, 2024

Office of the Vermont (VT) Attorney General

Submitted via email: AGO.highcostprescriptiondrugs@vermont.gov

Re: New Prescription Drug Notice from Novo Nordisk Inc. – RIVFLOZA™

Dear Office of the Attorney General,

Pursuant to 18 V.S.A. § 4637 (b), Novo Nordisk Inc. is providing notification of a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under the Medicare Part D program.

NDC	Drug Product Description	Introduced to Market Date	WAC at Intro to Market
00169-5308-01	RIVFLOZA™ 80 mg/0.5 mL (160 mg/mL) in 1 single-dose vial	2/19/2024	\$31,440.00
00169-5307-08	RIVFLOZA™ 128 mg/0.8 mL (160 mg/mL) in 1 single-dose pre-filled syringe	2/19/2024	\$50,304.00
00169-5306-10	RIVFLOZA™ 160 mg/mL in 1 single-dose pre-filled syringe	2/19/2024	\$62,880.00

We will submit to the Office the additional information required under 18 V.S.A. §4637 (b) within 30 days of this initial submission.

Should you have any questions, please contact me at (484) 890-3714 or AJBV@novonordisk.com.

Sincerely,

Anthony (AJ) Brunovsky
Senior Manager, Government Accountability
Ethics & Compliance
Novo Nordisk Inc.